To date, in available literature, there is only one publication that contains data on influence of any of the polymorphisms in the STMN1 gene (including −2166T>C, rs182455) on the effectiveness of any of the currently used CTH regimens in lung cancer [13]. This evidence concerns the gene STMN1 and lung cancer.